Markus G Manz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4634535/publications.pdf

Version: 2024-02-01

188 papers	17,903 citations	28190 55 h-index	13727 129 g-index
201 all docs	201 docs citations	201 times ranked	22297 citing authors

#	Article	IF	Citations
1	Development of Monocytes, Macrophages, and Dendritic Cells. Science, 2010, 327, 656-661.	6.0	2,471
2	Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice. Science, 2004, 304, 104-107.	6.0	934
3	BIOLOGY OFHEMATOPOIETICSTEMCELLS ANDPROGENITORS: Implications for Clinical Application. Annual Review of Immunology, 2003, 21, 759-806.	9.5	888
4	Development and function of human innate immune cells in a humanized mouse model. Nature Biotechnology, 2014, 32, 364-372.	9.4	629
5	Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nature Immunology, 2007, 8, 1207-1216.	7.0	628
6	Emergency granulopoiesis. Nature Reviews Immunology, 2014, 14, 302-314.	10.6	625
7	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. New England Journal of Medicine, 2018, 378, 1189-1199.	13.9	605
8	Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nature Cell Biology, 2016, 18, 607-618.	4.6	519
9	Flt3 Ligand Regulates Dendritic Cell Development from Flt3+ Lymphoid and Myeloid-committed Progenitors to Flt3+ Dendritic Cells In Vivo. Journal of Experimental Medicine, 2003, 198, 305-313.	4.2	513
10	Prospective isolation of human clonogenic common myeloid progenitors. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11872-11877.	3.3	460
11	Development of CD8Â-Positive Dendritic Cells from a Common Myeloid Progenitor. Science, 2000, 290, 2152-2154.	6.0	363
12	Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood, 2001, 97, 3333-3341.	0.6	357
13	Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood, 2012, 119, 2991-3002.	0.6	351
14	BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. Journal of Experimental Medicine, 2014, 211, 669-683.	4.2	346
15	Dendritic cell homeostasis. Blood, 2009, 113, 3418-3427.	0.6	332
16	Human Hemato-Lymphoid System Mice: Current Use and Future Potential for Medicine. Annual Review of Immunology, 2013, 31, 635-674.	9.5	304
17	Engineering of a functional bone organ through endochondral ossification. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3997-4002.	3.3	289
18	Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment. Frontiers in Immunology, 2016, 7, 502.	2.2	272

#	Article	IF	Citations
19	Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. Journal of Experimental Medicine, 2011, 208, 273-284.	4.2	271
20	Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-Âc-/- mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15951-15956.	3.3	224
21	Endothelial cells translate pathogen signals into G-CSFâ€“driven emergency granulopoiesis. Blood, 2014, 124, 1393-1403.	0.6	221
22	Pathogen-Induced TLR4-TRIF Innate Immune Signaling in Hematopoietic Stem Cells Promotes Proliferation but Reduces Competitive Fitness. Cell Stem Cell, 2017, 21, 225-240.e5.	5.2	210
23	Regulation of Inflammation- and Infection-Driven Hematopoiesis. Trends in Immunology, 2017, 38, 345-357.	2.9	209
24	Human-Hemato-Lymphoid-System Mice: Opportunities and Challenges. Immunity, 2007, 26, 537-541.	6.6	206
25	Transgenic expression of human signal regulatory protein alpha in Rag2^{â^'/â^'}Î³_c^{â^'/â^'}mice improves engraftment of human hematopoietic cells in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13218-13223.	3.3	205
26	Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2390-2395.	3.3	202
27	Microbiota-Derived Compounds Drive Steady-State Granulopoiesis via MyD88/TICAM Signaling. Journal of Immunology, 2014, 193, 5273-5283.	0.4	202
28	The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. Blood, 2009, 114, 835-843.	0.6	200
29	Human thrombopoietin knockin mice efficiently support human hematopoiesis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2378-2383.	3.3	169
30	Humanized hemato-lymphoid system mice. Haematologica, 2016, 101, 5-19.	1.7	166
31	Activation of the Flt3 signal transduction cascade rescues and enhances type I interferonâ€“producing and dendritic cell development. Journal of Experimental Medicine, 2006, 203, 227-238.	4.2	146
32	Efficient differentiation and function of human macrophages in humanized CSF-1 mice. Blood, 2011, 118, 3119-3128.	0.6	134
33	Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nature Medicine, 2016, 22, 1351-1357.	15.2	132
34	CD34+CD38â^' leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia, 2019, 33, 1102-1112.	3.3	130
35	Cutting Edge: LPS-Induced Emergency Myelopoiesis Depends on TLR4-Expressing Nonhematopoietic Cells. Journal of Immunology, 2012, 188, 5824-5828.	0.4	129
36	Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nature Medicine, 2020, 26, 1459-1467.	15.2	122

#	Article	IF	Citations
37	Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement. Trends in Immunology, 2011, 32, 321-327.	2.9	117
38	Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. Journal of Experimental Medicine, 2021, 218, .	4.2	113
39	Quantitative spatial analysis of haematopoiesis-regulating stromal cells in the bone marrow microenvironment by 3D microscopy. Nature Communications, 2018, 9, 2532.	5.8	109
40	A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. Blood, 2017, 129, 959-969.	0.6	105
41	Clonal Type I Interferonâ€“producing and Dendritic Cell Precursors Are Contained in Both Human Lymphoid and Myeloid Progenitor Populations. Journal of Experimental Medicine, 2004, 200, 1519-1524.	4.2	103
42	Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 9701-9706.	3.3	97
43	Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. Journal of Experimental Medicine, 2014, 211, 2213-2230.	4.2	88
44	Quantification and three-dimensional microanatomical organization of the bone marrow. Blood Advances, 2017, 1, 407-416.	2.5	84
45	Renaissance for mouse models of human hematopoiesis and immunobiology. Nature Immunology, 2009, 10, 1039-1042.	7.0	81
46	Peripheral blood CD34+ cells efficiently engraft human cytokine knock-in mice. Blood, 2016, 128, 1829-1833.	0.6	80
47	Global Transcriptomic Profiling of the Bone Marrow Stromal Microenvironment during Postnatal Development, Aging, and Inflammation. Cell Reports, 2019, 29, 3313-3330.e4.	2.9	79
48	Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood, 2017, 129, 1636-1645.	0.6	77
49	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCHâ€associated neurodegeneration and mass lesions. Cancer, 2018, 124, 2607-2620.	2.0	73
50	The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell, 2021, 39, 288-293.	7.7	71
51	Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host and Microbe, 2021, 29, 1573-1588.e7.	5.1	71
52	Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSFâ€“licensed myeloid cells. Science Translational Medicine, 2018, 10, .	5.8	68
53	Bone marrow dendritic cell progenitors sense pathogens via Toll-like receptors and subsequently migrate to inflamed lymph nodes. Blood, 2011, 118, 4829-4840.	0.6	62
54	HTLV-1 Propels Thymic Human T Cell Development in â€œHuman Immune Systemâ€•Rag2-/- gamma c-/- Mice. PLoS Pathogens, 2011, 7, e1002231.	2.1	61

#	Article	IF	Citations
55	A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies. Nature Communications, 2019, 10, 366.	5.8	60
56	Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood, 2020, 135, 1548-1559.	0.6	58
57	iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports, 2020, 14, 49-59.	2.3	57
58	Inhibition of Natural Type I IFN-Producing and Dendritic Cell Development by a Small Molecule Receptor Tyrosine Kinase Inhibitor with Flt3 Affinity. Journal of Immunology, 2005, 175, 3674-3680.	0.4	56
59	Macrophage tolerance: CD47â€“SIRP-Î±â€“mediated signals matter. Nature Immunology, 2007, 8, 1287-1289.	7.0	56
60	Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice. PLoS Pathogens, 2013, 9, e1003587.	2.1	55
61	Controlled Cycling and Quiescence Enables Efficient HDR in Engraftment-Enriched Adult Hematopoietic Stem and Progenitor Cells. Cell Reports, 2020, 32, 108093.	2.9	54
62	NLRP3 Controls the Development of Gastrointestinal CD11b + Dendritic Cells in the Steady State and during Chronic Bacterial Infection. Cell Reports, 2017, 21, 3860-3872.	2.9	52
63	Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia, 2020, 34, 2688-2703.	3.3	52
64	IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice. Blood, 2022, 139, 44-58.	0.6	51
65	Sensing and translation of pathogen signals into demand-adapted myelopoiesis. Current Opinion in Hematology, 2016, 23, 5-10.	1.2	50
66	A novel mouse model for inhibition of DOHH mediated hypusine modification reveals crucial function for embryonic development, proliferation and oncogenic transformation. DMM Disease Models and Mechanisms, 2014, 7, 963-76.	1.2	46
67	Lymphotoxin Î² Receptor Signaling Promotes Development of Autoimmune Pancreatitis. Gastroenterology, 2012, 143, 1361-1374.	0.6	45
68	Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nature Communications, 2021, 12, 6436.	5.8	45
69	Enhanced thrombopoietin but not G-CSF receptor stimulation induces self-renewing hematopoietic stem cell divisions in vivo. Blood, 2016, 127, 3175-3179.	0.6	44
70	Sensitive Quantitative Proteomics of Human Hematopoietic Stem and Progenitor Cells by Data-independent Acquisition Mass Spectrometry. Molecular and Cellular Proteomics, 2019, 18, 1454-1467.	2.5	43
71	Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications. Nature Chemistry, 2021, 13, 540-548.	6.6	42
72	The tumor suppressive TGF-Î²/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. Blood, 2018, 131, 2235-2246.	0.6	41

#	Article	IF	Citations
73	inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice. Blood, 2016, 128, 2130-2134.	0.6	40
74	DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. Nature Cell Biology, 2014, 16, 812-820.	4.6	39
75	The <scp>IL</scp> â€6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large Bâ€cell lymphoma. EMBO Molecular Medicine, 2019, 11, e10576.	3.3	38
76	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature Medicine, 2021, 27, 851-861.	15.2	38
77	Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. Blood, 2016, 127, 3253-3259.	0.6	37
78	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. Nature Communications, 2021, 12, 6703.	5.8	36
79	Impact of inflammation on early hematopoiesis and the microenvironment. International Journal of Hematology, 2017, 106, 27-33.	0.7	35
80	MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. Blood, 2016, 128, 2253-2257.	0.6	34
81	Neurological complications of cancer immunotherapy. Cancer Treatment Reviews, 2021, 97, 102189.	3.4	34
82	Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Advances, 2021, 5, 1110-1121.	2.5	33
83	Asymmetric organelle inheritance predicts human blood stem cell fate. Blood, 2022, 139, 2011-2023.	0.6	32
84	Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 214.e1-214.e11.	0.6	32
85	Dendritic cell homeostasis is maintained by nonhematopoietic and <scp>T</scp>â€cellâ€produced <scp>F</scp>lt3â€ligand in steady state and during immune responses. European Journal of Immunology, 2013, 43, 1651-1658.	1.6	31
86	Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice. Journal of Virology, 2015, 89, 6761-6772.	1.5	30
87	The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica, 2019, 104, 710-716.	1.7	29
88	Chronic viral infections persistently alter marrow stroma and impair hematopoietic stem cell fitness. Journal of Experimental Medicine, 2021, 218, .	4.2	27
89	Safety and efficacy of cryopreserved autologous platelet concentrates in HLAâ€alloimmunized patients with hematologic malignancies. Transfusion, 2016, 56, 2426-2437.	0.8	26
90	Clonal dominance and transplantation dynamics in hematopoietic stem cell compartments. PLoS Computational Biology, 2017, 13, e1005803.	1.5	26

#	Article	IF	Citations
91	Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response. Journal of Clinical Investigation, 2022, 132, .	3.9	26
92	NGS-pipe: a flexible, easily extendable and highly configurable framework for NGS analysis. Bioinformatics, 2018, 34, 107-108.	1.8	25
93	A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development. Journal of Proteomics, 2014, 99, 138-151.	1.2	24
94	Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiencyâ€"a case report and comprehensive review of the literature. Annals of Hematology, 2018, 97, 1961-1973.	0.8	24
95	Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection. Nature Communications, 2019, 10, 4986.	5.8	24
96	Clonal Hematopoiesis in Hospitalized Elderly Patients With COVIDâ€19. HemaSphere, 2020, 4, e453.	1.2	23
97	EBV renders B cells susceptible to HIV-1 in humanized mice. Life Science Alliance, 2020, 3, e202000640.	1.3	22
98	Cytokine combinations for human blood stem cell expansion induce cell-typeâ€“ and cytokine-specific signaling dynamics. Blood, 2021, 138, 847-857.	0.6	21
99	Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML). Leukemia and Lymphoma, 2017, 58, 1068-1075.	0.6	20
100	Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. Journal of Internal Medicine, 2018, 283, 371-379.	2.7	19
101	Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma. Blood Advances, 2019, 3, 3020-3032.	2.5	19
102	Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 2020, 34, 1751-1759.	3.3	18
103	Engineered humanized bone organs maintain human hematopoiesis in vivo. Experimental Hematology, 2018, 61, 45-51.e5.	0.2	17
104	Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia. Leukemia Research, 2019, 84, 106178.	0.4	17
105	Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial. Blood, 2018, 132, 2680-2680.	0.6	16
106	Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice. Blood Advances, 2020, 4, 2477-2488.	2.5	15
107	Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells. Experimental Hematology, 2021, 95, 31-45.	0.2	15
108	Inflammatory signals in HSPC development and homeostasis: Too much ofÂaÂgood thing?. Experimental Hematology, 2016, 44, 908-912.	0.2	14

#	Article	IF	Citations
109	Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. JCO Precision Oncology, 2017, 1, 1-13.	1.5	14
110	Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood Advances, 2020, 4, 4267-4277.	2.5	14
111	Fate Distribution and Regulatory Role of Human Mesenchymal Stromal Cells in Engineered Hematopoietic Bone Organs. IScience, 2019, 19, 504-513.	1.9	13
112	Generation of Humanized Mice for Analysis of Human Dendritic Cells. Methods in Molecular Biology, 2016, 1423, 309-320.	0.4	12
113	Impact of Ligand Size and Conjugation Chemistry on the Performance of Universal Chimeric Antigen Receptor T-Cells for Tumor Killing. Bioconjugate Chemistry, 2020, 31, 1775-1783.	1.8	12
114	R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20Âyears of single-center experience. Annals of Hematology, 2018, 97, 277-287.	0.8	11
115	Plasmacytoid dendritic cells: origin matters. Nature Immunology, 2018, 19, 652-654.	7.0	11
116	Daratumumab in rituximabâ€refractory autoimmune haemolytic anaemia. British Journal of Haematology, 2021, 194, 931-934.	1.2	11
117	Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement. Oncologist, 2017, 22, 480-483.	1.9	10
118	A Single Metabolite which Modulates Lipid Metabolism Alters Hematopoietic Stem/Progenitor Cell Behavior and Promotes Lymphoid Reconstitution. Stem Cell Reports, 2020, 15, 566-576.	2.3	10
119	Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving<scp>l</scp>-asparaginase. Leukemia and Lymphoma, 2018, 59, 855-862.	0.6	9
120	A novel dual-cytokineâ€“antibody fusion protein for the treatment of CD38-positive malignancies. Protein Engineering, Design and Selection, 2018, 31, 173-179.	1.0	9
121	A pilot clinical phase II trial MemSID: Acute and durable changes of red blood cells of sickle cell disease patients on memantine treatment. EJHaem, 2020, 1, 23-34.	0.4	9
122	CXCL12-abundant reticular cells are the major source of IL-6 upon LPS stimulation and thereby regulate hematopoiesis. Blood Advances, 2021, 5, 5002-5015.	2.5	9
123	Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. Cancer Epidemiology, 2018, 52, 55-62.	0.8	8
124	Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans. Blood, 2019, 134, 234-234.	0.6	8
125	Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: A real-world, retrospective comparative single-centre study. Swiss Medical Weekly, 2014, 144, w13985.	0.8	8
126	Specific Inhibitor of Placental Alkaline Phosphatase Isolated from a DNA-Encoded Chemical Library Targets Tumor of the Female Reproductive Tract. Journal of Medicinal Chemistry, 2021, 64, 15799-15809.	2.9	8

#	Article	IF	Citations
127	TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms. Blood Advances, 2022, 6, 3201-3206.	2.5	8
128	Long-Term Follow-Up of Antibody Titers Against Measles, Mumps, and Rubella in Recipients of Allogenic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 581-592.	2.0	7
129	Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 2021, 13, 672.	1.7	7
130	Disruption of CSF-1R signaling inhibits growth of AML with inv(16). Blood Advances, 2021, 5, 1273-1277.	2.5	7
131	Clonal hematopoiesis in hematopoietic stem cell transplantation. Current Opinion in Hematology, 2021, 28, 94-100.	1.2	7
132	BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cellâ€“like histiocytosis in immune-deficient mice. Blood Advances, 2020, 4, 4912-4917.	2.5	6
133	SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues. Leukemia Research, 2021, 107, 106608.	0.4	6
134	Preclinical Assessment of CDR101 - a BCMAxCD3xPD-L1 Trispecific Antibody with Superior Anti-Tumor Efficacy. Blood, 2021, 138, 1583-1583.	0.6	6
135	In vivo divisional tracking of hematopoietic stem cells. Annals of the New York Academy of Sciences, 2012, 1266, 40-46.	1.8	5
136	Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. Experimental Hematology and Oncology, 2014, 3, 18.	2.0	5
137	Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 811-815.	0.2	5
138	Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia. Hematological Oncology, 2018, 36, 471-480.	0.8	5
139	Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study. Biology of Blood and Marrow Transplantation, 2018, 24, 694-699.	2.0	5
140	The Innate Immune Response to Infection Induces Erythropoietin-Dependent Replenishment of the Dendritic Cell Compartment. Frontiers in Immunology, 2020, 11, 1627.	2.2	5
141	MEMSID: Results From a Phase 2ÂPilot Study on Memantine Treatment for Sickle Cell Disease. HemaSphere, 2020, 4, e452.	1.2	5
142	Reduced CXCL4/PF4 expression as a driver of increased human hematopoietic stem and progenitor cell proliferation in polycythemia vera. Blood Cancer Journal, 2021, 11, 31.	2.8	5
143	Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Annals of Hematology, 2021, 100, 1169-1179.	0.8	5
144	Bimodal expression of potential drug target CLLâ€1 (CLEC12A) on CD34+ blasts of AML patients. European Journal of Haematology, 2021, 107, 343-353.	1.1	5

#	Article	IF	Citations
145	Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14. Blood, 2016, 128, 3108-3108.	0.6	4
146	Next Generation Humanized Mice Support Engraftment of Myelofibrosis CD34+ Cells. Blood, 2014, 124, 1880-1880.	0.6	4
147	Selective CD117+ HSC exchange therapy. Blood, 2019, 133, 2007-2009.	0.6	3
148	Humanized Mouse Model of Myeloma Reveals Clinically Occult Genomic Changes in Primary Tumor Cells. Blood, 2015, 126, 22-22.	0.6	3
149	The added value of multiâ€state modelling in a randomized controlled trial: The HOVON 102 study reâ€analyzed. Cancer Medicine, 2022, 11, 630-640.	1.3	3
150	Marginal Zone Lymphoma Complicated by Protein Losing Enteropathy. Case Reports in Hematology, 2016, 2016, 1-5.	0.3	2
151	Finally: development of humanized lymph nodes. Nature Methods, 2018, 15, 580-582.	9.0	2
152	Efficient Human Acute Myeloid Leukemia Targeting By Universal Chimeric Antigen Receptor T-Cells Via Combinatorial Use of Linkers. Blood, 2021, 138, 2781-2781.	0.6	2
153	Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells. Blood Advances, 2022, , .	2.5	2
154	A microbiome-macrophage-iron axis guides stressed hematopoietic stem cell fate. Cell Stem Cell, 2022, 29, 177-179.	5.2	2
155	Dynamic regulation of hematopoietic stem cell cycling. Cell Cycle, 2011, 10, 2246-2247.	1.3	1
156	sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-Î± therapy. Annals of Hematology, 2017, 96, 757-763.	0.8	1
157	Efficacy of selective digestive decontamination in patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell transplantation. Leukemia and Lymphoma, 2019, 60, 685-695.	0.6	1
158	JAK2-V617F Expressing Stem Cells Display a Competitive Advantage At Low Limiting Dilution and Are Capable of Initiating MPN Phenotype. Blood, 2011, 118, 615-615.	0.6	1
159	ÎœÎ™SÎRG Mice Support Good-Risk AML Engraftment. Blood, 2014, 124, 3808-3808.	0.6	1
160	Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice. Blood, 2015, 126, 120-120.	0.6	1
161	Baseline creatinine predicts acute kidney injury during intensive therapy in transplantâ€eligible patients with acute myeloid leukaemia. British Journal of Haematology, 2021, , .	1.2	1
162	A Bispecific Antibody Targeting CD117 and CD3 Enables T Cell Mediated Killing of CD117-Expressing Healthy and Malignant Hematopoietic Cells. Blood, 2021, 138, 2354-2354.	0.6	1

#	Article	IF	Citations
163	Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells. Blood, 2021, 138, 2808-2808.	0.6	1
164	Plasmacytoid dendritic cells: ready to be tested in vivo. Blood, 2001, 98, 3503-3503.	0.6	0
165	THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA. Hematological Oncology, 2019, 37, 127-127.	0.8	0
166	Pegylated interferon can control myelodysplastic/myeloproliferative syndrome with ring sideroblasts and thrombocytosis. Leukemia and Lymphoma, 2020, 61, 2533-2535.	0.6	0
167	PL03.3.A Development and characterization of CD317-specific CAR T cells as an innovative immunotherapeutic strategy against glioblastoma. Neuro-Oncology, 2021, 23, ii2-ii2.	0.6	0
168	Non-Hematopoietic Stromal Cells Sense Toll-Like Receptor 4 Agonists and Consequently Enhance Myelopoiesis.. Blood, 2010, 116, 2583-2583.	0.6	0
169	Allogeneic Transplantation for Multiple Myeloma â€“ the Swiss Experience. Blood, 2011, 118, 3112-3112.	0.6	0
170	Engraftment Of Human Polycythemia Vera CD34+ Cells In hSIRPÎ±-Transgenic-Human-TPO-Expressing RAG2-/-, IL2RÎ³-/- Immunodeficient Mice. Blood, 2013, 122, 2844-2844.	0.6	0
171	Hematopoietic Stem Cells and Circulating Myelomonocytic Precursors With BRAF-V600E Are Identified In High-Risk Patients and Define LCH As a Myeloid Neoplasia. Blood, 2013, 122, 103-103.	0.6	0
172	Direct Sensing of Lipopolysaccharide Limits Hematopoietic Stem Cell Selfrenewal Via TLR4-TRIF-ROS-p38 Pathway. Blood, 2014, 124, 604-604.	0.6	0
173	Adult Donor-Derived Human CD34+ Cell Engraftment and Hemato-Lymphoid System Development in 3rd Generation Humanized Mice. Blood, 2014, 124, 4378-4378.	0.6	0
174	Interleukin-1 Drives Precocious Myeloid Differentiation of Hematopoietic Stem Cells at the Expense of Self-Renewal. Blood, 2015, 126, 778-778.	0.6	0
175	Mpl Expression on AML Blasts Predicts Cytopenia. Blood, 2015, 126, 1387-1387.	0.6	0
176	The Bone Marrow Microenvironment Is a Target of Graft-Vs-Host Reactivity Following Allogeneic Hematopoietic Cell Transplantation in Mice. Blood, 2016, 128, 4539-4539.	0.6	0
177	CXCL12-Abundant Reticular (CAR) Cells Are Key Regulators for a Sustained Hematopoietic Response during Chronic Inflammation. Blood, 2016, 128, 429-429.	0.6	0
178	BRAFV600E Transduced Human CD34+ Cells Establish Aggressive Langerhans Cell Histiocytosis in Humanized Mice. Blood, 2016, 128, 2739-2739.	0.6	0
179	Inv(16) AML Engrafts Human Cytokine Knock-in Mice. Blood, 2016, 128, 1078-1078.	0.6	0
180	Improvement of Relative Survival in Elderly Patients with Acute Myeloid Leukemia Emerging from Population-Based Cancer Registries in Switzerland from 2001-2013. Blood, 2017, 130, 863-863.	0.6	0

#	Article	IF	Citations
181	Graft-Vs-Host Reactivity Against the Bone Marrow Is Directed Against the Hematopoietic and Non-Hematopoietic Compartments in Mice. Blood, 2018, 132, 808-808.	0.6	0
182	IMMU-39. EVALUATION OF CD317-TARGETING CAR T CELLS AS A NOVEL IMMUNOTHERAPEUTIC STRATEGY AGAINST GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi101-vi101.	0.6	0
183	Clonal Expansion of Tet2 +/- hematopoiesis Is Driven By Inflamm-Ageing Associated IL-1 Increase in Mice. Blood, 2021, 138, 1086-1086.	0.6	0
184	CD117 As an Immunotherapeutic Target in Advanced Forms of Mastocytosis. Blood, 2021, 138, 2538-2538.	0.6	0
185	Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 3894-3894.	0.6	0
186	Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10Âyears. Annals of Hematology, 2022, 101, 1097-1106.	0.8	0
187	Romiplostim addition to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels. Blood Advances, 0, , .	2.5	0
188	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients. Journal of Molecular Diagnostics, 2022, , .	1.2	0